Please use this identifier to cite or link to this item:
標題: Association between expressions of KIT with PI3K/AKT/mTOR signal transduction pathway and clinicopathological factors in canine cutaneous mast cell tumors
作者: Cho-Hau Yang
關鍵字: KIT蛋白

immunohistochemical staining
引用: Abadie, J.J., Amardeilh, M.A., Delverdier, M.E., 1999. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. Journal of the American Veterinary Medical Association 215, 1629-1634. Akin, C., Metcalfe, D.D., 2004. The biology of Kit in disease and the application of pharmacogenetics. Journal of Allergy and Clinical Immunology 114, 13-19. Alessi, D.R., Andjelkovic, M., Caudwell, B,, Cron, P., Morrice, N., Cohen, P., Hemmings, B.A., 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO Journal 15, 6541-6551. Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., Cohen, P., 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Current Biology 7, 261-269. Ali, K., Bilancio, A., Thomas, M., Pearce, W., Gilfillan, A.M., Tkaczyk, C., Kuehn, N., Gray, A., Giddings, J., Peskett, E., Fox, R., Bruce, I., Walker, C., Sawyer, C., Okkenhaug, K., Finan, P., Vanhaesebroeck, B. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431, 1007-1011. Allan, G.S., Gilette, E.L., 1979. Response of canine mast cell tumors to radiation. Journal of the National Cancer Institute 63, 691-694. al-Sarraf, R., Mauldin, G.N., Patnaik, A.K., Meleo, K.A., 1996. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. Journal of Veterinary Internal Medicine 10, 376-378. Anderson, K.E., Coadwell, J., Stephens, L.R., Hawkins, P.T., 1998. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Current Biology 8, 684-691. Andre, F., Nahta, R., Conforti, R., Boulet, T., Aziz, M., Yuan, L.X., Meslin, F., Spielmann, M., Tomasic, G., Pusztai, L., Hortobagyi, G.N., Michiels, S., Delaloge, S., Esteva, F.J., 2008. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 19, 315-320. Baird, K., Davis, S., Antonescu, C.R., Harper, U.L., Walker, R.L., Chen, Y., Glatfelter, A.A., Duray, P.H., Meltzer, P.S., 2005. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Research 65, 9226-9235. Bellacosa, A., Testa, J.R., Staal, S.P., Tsichlis, P.N., 1991. A retroviral oncogene, akt encoding a serine-threonine kinase containing an SH2-like region. Science 254, 274-277. Bergman, P.J., 2013. Paraneoplastic syndrome. In: Withrow & MacEwen's Small animal clinical oncology, Fifth Ed. Missouri: Saunders Elsevier Co., St. Louis, USA, pp. 83-85. Bostock, D.E., 1973. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice 14, 27-41. Bostock, D.E., 1986. Neoplasms of the skin and subcutaneous tissues in dogs and cats. British Veterinary Journal 142, 1-19. Bostock, D.E., Crocker, J., Harris, K., Smith, P., 1989. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumor. British Journal of Cancer 59(6), 915-918. Bougherara, H., Subra, F., Crepin, R., Tauc, P., Auclair, C., Poul, M.A., 2009. The aberrant localization of oncogenic Kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Molecular Cancer Research 7, 1525-1533. Brognard, J., Clark, A.S., Ni, Y., Dennis, P.A., 2001. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Research 61, 3986-3997. Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S., Schreiber, S.L., 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756-758. Byers, J.C., Fleischman, R.W., 1981. Peptic ulcers associated with a mast cell tumor in a dog. Canine Practice 8, 42-44. Camp-Palau, M.A., Leibman, N.F., Elmslie, R., Lana, S.E., Plaza, S., McKnight, J.A., Risbon, R., Bergman, P.J., 2007. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Veterinary and Comparative Oncology 5, 156-167. Cantley, L.C., 2002. The phosphoinositide 3-kinase pathway. Science 296, 1655-1657. Cantrell, D.A., 2001. Phosphoinositide 3-kinase signaling pathways. Journal of Cell Science 114, 1439-1445. Carnero, A., 2010. The PKB/AKT pathway in cancer. Current Pharmaceutical Design 16, 34-44. Chang, J.C., 2010. Overexpression of epidermal growth factor receptor signal pathways in dogs and cats with soft tissue and bone sarcomas. Thesis, Master of Veterinary Medicine, University of National Chung-Hsin. Chatterjee, M., Andrulis, M., Stuhmer, T., Muller, E., Hofmann, C., Steinbrunn, T., Heimberger, T., Schraud, H., Kressmann, S., Einsele, H., Bargou, R.C., 2013. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 98(7), 1132-1141. Chen, Y.T., Tan, K.A.L., Pang, L.Y., Argyle, D.J., 2012. The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Veterinary Research 8, 73-87. Chiu, M.I., Katz, H., Berlin, V., 1994. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proceedings of the National Academy of Sciences of the United States of America 91, 12574-12578. Chung, J.Y., Hong, S.M., Choi, B.Y., Cho, H., Yu, E., Hewitt, S.M., 2009. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clinical Cancer Research 15(2), 660-667. Cooper, M., Tsai, X., Bennett, P., 2009. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Veterinary and Comparative Oncology 7, 196-206. Crowe, D.T., Goodwin, M.A., Greene, C.E., 1986. Total laryngectomy for laryngeal mast cell tumor in a dog. Journal of the American Animal Hospital Association 22, 809-816. Davis, B.J., Page, R., Sannes, P.L., Meuten, D.J., 1992. Cutaneous mastocytosis in a dog. Veterinary Pathology 29, 363-365. Dean, P.W., 1988. Mast cell tumors in dog: diagnosis, treatment, and prognosis. Veterinary Medicine 83, 185-188. De Souza, M.L., Torres, L.F., Rocha, N.S., Takahira, R.K.,Mamprim, M.J., Burini, C.H.P., Bandarra, E.P., Figueiredo, L.M.A., 2001. Peritoneal effusion in a dog secondary to visceral mast cell tumor. A case report. Journal of Clinical Cytology and Cytopathology 45, 89-92. De Strefezzi, R., Xavier, J.G., Catao-Dias, T.L., 2003. Morphometry of canine cutaneous mast cell tumors. Veterinary Pathology 40, 268-275. Dobson, J.M., Cohen, S., Gould, S., 2004. Treatment of canine MCTs with prednisolone and radiotherapy. Veterinary and Comparative Oncology 2, 132-141. Dobson, J.M., Scase, T.J., 2007. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. Journal of Small Animal Practice 48, 424-431. Downing, S., Chien, M.B., Kass, P.H., Moore, P.E., London, C.A., 2002. Prevalence and importance of internal tandem duplications in exons11 and 12 of c-kit in mast cell tumors of dogs. American Journal of Veterinary Research 63, 1718-1723. Engelman, J.A., 2009. Targeting PI3K signaling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer 9, 550-562. Engelman, J.A., Luo, J., Cantley, L.C., 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics 7, 606-619. Faivre, S., Kroemer, G., Raymond, E., 2006. Current development of mTOR inhibitors as anticancer agents. Nature Review Drug Discovery 5, 671-688. Fox, L.E., Rosenthal, R.C., Twedt, D.C., Dubielzig, R.R., MacEwen, E.G., Grauer, G.F., 1990. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. Journal of Veterinary Internal Medicine 4, 242-246. Frimberger, A.E., Moore, A.S., LaRue, S.M., Gliatto, J.M., Bengtson, A.E., 1997. Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993). Journal of the American Animal Hospital Association 33, 320-324. Fulcher, R.P., Ludwig, L.L., Bergman, P.J., Newman, S.J., Simpson, A.M., Patnaik, A.K., 2006. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Journal of the American veterinary medical association 228, 210-215. Galli, S.J., Zsebo, K.M., Geissler, E.N., 1994. The kit ligand, stem cell factor. Advances in immunology 55, 1-95. Gerritsen, R.J., Teske, E., Kraus, J.S., Rutteman, G.R., 1998. Multi-agent chemotherapy for mast cell tumours in the dog. Veterinary quarterly 20, 28-31. Gibson, P.C., Cooper, K., 2002. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Advances in anatomic pathology 9, 65-69. Gieger, T.L., Theon, A.P., Werner, J.A., McEntee, M.C., Rassnick, K.M., DeCock, H.E., 2003. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). Journal of veterinary internal medicine 17, 687-692. Gil da Costa, R.M., Matos, E., Rema, A., Lopes, C., Pires, M.A., Gartner, F., 2007. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers. BMC veterinary research 3, 19. Goldschmidt, M.H., Shofer F.S., 1992. Mast cell tumors. In: Skin Tumors of the Dog and Cat. New York: Pergamon Press, pp. 231-251. Govier, S.M., 2003. Principles of treatment for mast cell tumors. Clinical techniques in small animal practice 18, 103-106. Hahn, K,A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P.S., Kinet, J.P., Palmerini, F., Dubreuil, P., Moussy, A., Hermine, O., 2008. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of veterinary internal medicine 22, 1301-1309. Haslam, R.J., Koide, H.B., Hemmings, B.A., 1993. Pleckstrin domain homology. Nature 363, 309-310. Hayes, A., Adams, V., Smith, K., Maglennon, G., Murphy, S., 2007. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Veterinary and comparative oncology 5, 168-176. Heitman, J., Movva, N.R., Hall, M.N., 1991. Target for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905-909. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., Mills, G.B., 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature 4, 988-1004. Howard, E.B., Sawa, T.R., Nielsen, S.W., Kenyon, A.J., 1969. Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Veterinary pathology 6, 146-158. Hume, C.T., Kiupel, M., Rigatti, L., Shofer, F.S., Skorupski, K.A., Sorenmo, K.U., 2011. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). Journal of the American animal hospital association 47, 37-44. Isotani, M., Ishida, N., Tominaga, M., Tamura, K., Yagihara, H., Ochi, S., Kato, R., Lobayashi, T., Fujita, M., Fujino, Y., Setoguchi, A., Ono, K., Washizu, T., Bonkobara, M., 2008. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. 22, 985-988. Iwata, N., Ochiai, K., Kadosawa, T., Takiguchi, M., Umemura, T., 2000. Canine extracutaneous mast-cell tumours consisting of connective tissue mast cells. Journal of comparative pathology 123, 306-310. Jiang, B.H., Liu, L.Z., 2008. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochimica et biophysica acta 1784, 150-158. Jones, C.L., Grahn, R.A., Chien, M.B., Lyons, L.A., London, C.A., 2004. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. Journal of Veterinary Diagnostic Investigation 16, 95-100. Jones, P.F., Jakubowicz, T., Pitossi, F.J., Maurer, F., Hemmings, B.A., 1991. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proceedings of the National Academy of Sciences of the United States of America 88, 4171-4175. Kandel, E.S., Hay, N., 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Experimental Cell Research 253, 210-229. Kim, C.S., Vasko, V.V., Kato, Y., Kruhlak, M., Saji, M., Cheng, S.Y., Ringel, M.D., 2005. Akt activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 146(10), 4456-4463. Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P., Sabatini, D.M., 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175. Kim, D.H., Sarbassov, D.D., Ali, S.M., Latek, R.R., Guntur, K.V., Erdjument-Bromage, H., Tempst, P., Sabatini, D.M., 2003. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Molecular Cell 11, 895-904. Kim, D., Kim, S., Koh, H., Yoon, S.O., Chung, A.S., Cho, K.S., Chang, J., 2001. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. The Journal of the Federation of American Societies for Experimental Biology 15, 1953-1962. Kim, M.S., Kuehn, H.S., Metcalfe, D.D., Gilfillan, A.M., 2008. Activation and function of the mTORC1 pathway in mast cells. The Journal of Immunology 180, 4586-4596. Kiupel, M., Webster, J.D., Bailey, K.L., Best, S., DeLay, J., Detrisac, C.J., Fitzqerald, S.D., Gamble, D., Ginn, P.E., Goldschmidt, M.H., Hendrick, M.J., Howerth, E.W., Janovitz, E.B., Lanqohr, I., Lenz, S.D., Lipscomb, T.P., Miller, M.A., Misdorp, W., Moroff, S., Mullaney, T.P., Neyens, I., O'Toole, D., Ramos-Vara, J., Scase, T.J., Schulman, F.Y., Sledge, D., Smedley, R.C., Smith, K., W Snyder, P., Southorn, E., Stedman, N.L., Steficek, B.A., Stromberq, P.C., Valli, V.E., Weisbrode, S.E., Yaqer, J., Heller, J., Miller, R., 2011. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary pathology 48, 147-155. Kiupel, M., Webster, J.D., Kaneene, J.B., Miller, R., Yuzbasiyan-gurkan, V., 2004. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Veterinary pathology 41, 371-377. Kiupel, M., Webster, J.D., Miller, R.A., Kaneene, J.B., 2005. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. Journal of veterinary medicine. A, Physiology, pathology, clinical medicine 52, 280-286. Kobie, K., Kawabata, M., Hioki, K., Tanaka, A., Matsuda, H., Mori, T., Maruo, K., 2007. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Research in veterinaryscience 82, 239-241. Kravis, L.D., Vail, D.M., Kisseberth, W.C., Ogilvie, G.K., Volk, L.M., 1996. Frequency of argyrophilic nucleolar organizer regions in fine needle aspirates and biopsy specimens from mast cell tumors in dogs. Journal of the American veterinary medical association 209, 1418-1420. LaDue, T., Price, G.S., Dodge, R., Page, R.L., Thrall, D.E., 1998. Radiation therapy for incompletely resected canine mast cell tumors. Veterinary radiology and ultrasound 39, 57-62. Leevers, S.J., Vanhaesebroeck, B., Waterfied, M.D., 1999. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Current opinion in cell biology 11, 219-225. Lemarie, R.J., Lemarie, S.L., Hedlund, C.S., 1995. Mast-cell tumors-clinical management. Compendium Continuing Education for the Practicing Veterinarian 17, 1085-1101. Letard, S., Yang., Hanssens, K., Palmerini, F., Leventhal, P.S., Guery, S., Moussy, A., Kinet, J.P., Hermine, O., Dubreuil, P., 2008. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Molecular cancer research : MCR 6, 1137-1145. Lin, X., Bohle, A.S., Dohrmann, P., Leuschner, I., Schulz, A., Kremer, B., Fandrich, F., 2001. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbeck's Archives of Surgery 386(4), 293-301. London, C.A., Galli, S.J., Yuuki, T., Hu, Z.Q., Helfand, S.C., Geissler, E.N., 1999. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology 27, 689-697. London, C.A., Kisseberth, W.C., Galli, S.J., Geissler, E.N., Helfand, S.C., 1996. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumors. Journal of Comparative Pathology 115, 399-414. London, C.A., Malpas, P.B., Wood-Follis, S.L., Boucher, J.F., Rusk, A.W., Rosenberg, M.P., Henry, C.J., Mitchener, K.L., Klein, M.K., Hintermeister, J.G., Bergman, P.J., Couto, G.C., Mauldin, G.N., Micheis, G.M., 2009. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical cancer research 15, 3856-3865. London, C.A., Seguin, B., 2003. Mast cell tumors in the dog. The Veterinary clinics of North America. Small animal practice 33, 473-489. London, C.A., Thamm, D.H., 2013. Mast cell tumors. In: Withrow & MacEwen's Small animal clinical oncology, Fifth Ed. Missouri: Saunders Elsevier Co., St. Louis, USA, pp. 336-337. MacEwen, E.G., Withrow, S., 1996. Canine mast cell tumors. In: Small Animal Oncology. Saunders Company, Philadelphia, pp. 402-403. Macy, D.W., 1986. Canine and feline mast cell tumors: biologic behavior, diagnosis and therapy. Seminars in veterinary medicine and surgery 1, 72-83. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., Cantley, L.C., 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Molecular cell 10, 151-162. Martin, D.E., Hall, M.N., 2005. The expanding TOR signaling network. Current opinion in cell biology 17, 158-166. Ma, Y., Longly, B.J., Wang, X., Blount, J.L., Langley, K., Caughey, G.H., 1999. Clustering of activating mutations in c-KIT/'s juxtamembrane coding region in canine mast cell neoplasms. Journal of Investigative Dermatology 112, 165-170. McCaw, D.L., Miller, M.A., Bergman, P.J., Withrow, S.J., Moore, A.S., Knapp, D.W., Fowler, D., Johnson, J.C., 1997. Vincristine therapy for mast cell tumors in dogs. Journal of veterinary internal medicine 11, 375-378. McCaw, D.L., Miller, M.A., Ogilvie, G.K., Withrow, S.J., Brewer, W.G., Jr., Klein, M.K., Bell, F.W., Anderson, S.K., 1994. Reponse of canine mast cell tumors to treatment with oral prednisone. Journal of veterinary internal medicine 8, 406-408. McClelland, R.B., 1964. The treatment of mastocytomas in dogs. The Cornell veterinarian 54, 517-519. Mcniel, E.A., Prink, A.L., O'Brien, T.D., 2006. Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Veterinary and comparative oncology 4, 2-8. Meier, F., Schittek, B., Busch, S., Garbe, C., Smalley, K., Satyamoorthy, K., Li, G., Herlyn, M., 2005. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in biosciences 10, 2986-3001. Meier, R., Alessi, D.R., Cron, P., Andjelkovic, M., Hemmings, B.A., 1997. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. The Journal of Biological Chemistry 272, 30491-30497. Michels, G.M., Knapp, D.W., DeNicola, D.B., Glickman, N., Bonney, P., 2002. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. Journal of the American animal hospital association 38, 458-466. Miettinen, M., Lasota, J., 2005. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Applied immunohistochemistry and molecular morphology 13, 205-220. Misdorp, W., 2004. Mast cells and canine mast cell tumours. A review. Veterinary quarterly 26(4), 156-169. Moore, L.E., Garrett, L.D., Debey, B., Biller, D.S., 2002. Spinal mast cell tumor in a dog. Journal of the American Animal Hospital Association 38, 67-70. Morini, M., Bettini, G., Preziosi, R., Mandrioli, L., 2004. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. Journal of histochemistry and cytochemistry 52, 705-708. Mullins, M.N., Dernell, W.S., Withrow, S.J., Ehrhart, E.J., Thamm, D.H., Lana, S.E., 2006. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). Journal of the American Veterinary Medical Association 228, 91-95. Murphy, S., Sparkes, A.H., Blunden, A.S., Brearley, M.J., Smith, K.C., 2006. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. The Veterinary record 158, 287-291. Murphy, S., Sparkes, A.H., Brearley, M.J., Smith, K.C., Blunden, A.S., 2004. Relationships between the histological grade of cutaneous mast cell tumors in dogs, their survival and the efficacy of surgical resection. Veterinary record 154, 743-746. Northrup, N.C., Howerth, E.W., Jarmon, B.G., Brown, C.A., Carmicheal, K.P., Garcia, A.P., Latimer, K.S., Munday, J.S., Rakich, P.M., Richey, L.J, Stedman, N.L., Gieger, T.L., 2005. Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 17, 561-564.
摘要: 犬體表型肥大細胞瘤為犬體表最常見之腫瘤。本實驗是利用免疫組織化學染色和免疫活性評分系統探討KIT/PI3K/Akt/mTOR訊息傳遞路徑在50個犬體表型肥大細胞瘤中的表現及活化情形,並進一步研究上述路徑中的蛋白與臨床病理因子之間的關係。在KIT的免疫組織化學染色中可發現,KIT有三種不同的分佈型態,分別為 (一) 只分佈在細胞膜、(二) 細胞質呈團聚集分佈和(三) 細胞質瀰漫性分佈,且此分佈型態與犬體表型肥大細胞瘤的組織學分級有顯著相關 (P = 0.004)。絕大多數組織學分級較低的腫瘤,其KIT分佈多屬於第二型;反之,在組織學分級較高的腫瘤,其KIT分佈多屬於第三型。當KIT分佈為第二型(92.6%, 25/27)或第三型(100%, 13/13) 時,癌化肥大細胞中的Akt會過度表現。在p-Akt的免疫組織化學染色中也可發現三種不同分佈型態,分別為 (一) 只分佈在細胞質、(二) 細胞質呈現較濃染,但細胞核呈現較稀疏染色和 (三) 細胞質與細胞核皆呈現陽性反應,但細胞核較濃染。腫瘤細胞內p-Akt的分佈,與KIT的分佈型態有顯著相關(P = 0.005),當KIT蛋白分佈為第一型時,p-Akt主要瀰漫分佈於細胞質(70.0%, 7/10);當KIT蛋白分佈為第三型時,p-Akt主要瀰漫分佈於細胞質及細胞核為主(61.5%, 8/13)。此外,本實驗發現p-Akt不同的分佈型態,與肥大細胞瘤的轉移有顯著的相關(P = 0.001)。在沒有發生轉移的肥大細胞瘤組織中可見多數的p-Akt只分佈在細胞質(51.7%, 15/27),而在有轉移的肥大細胞瘤組織中則見多數的p-Akt除了分佈在細胞質,也分佈在細胞核內且其表現較濃染(57.1%, 12/21)。當p-Akt活性增強時,下游的mTOR蛋白也會過度表現,而p-mTOR的活性也會隨之增加。實驗成果推測KIT/PI3K/Akt/mTOR訊息傳遞路徑在犬體表型肥大細胞瘤中扮演著重要角色,而p-Akt的分佈型態,可作為評估肥大細胞瘤患犬是否發生轉移的重要指標。
Mast cell tumors (MCTs) are one of the most common cutaneous tumors in the dog. This study aimed to evaluate KIT, PI3K, Akt, p-Akt, mTOR and p-mTOR expression in 50 canine cutaneous MCTs and investigate the correlations between the proteins mentioned above and clinicopathologic parameters by the immunohistochemical staining and immunoreactive score system. There were three KIT immunostaining patterns that are pattern I: primarily along the cytoplasmic membrane, pattern II: the intense, focally clustered cytoplasmic KIT staining, and pattern III: diffuse cytoplasmic staining and there was a significant difference between immunostaining patterns of KIT and grades of MCTs (P = 0.004). The majority low grade MCT was KIT-staining pattern II (64.5%, 20/31), while the high grade MCT was KIT-staining pattern III (52.6%, 10/19). When the expression of KIT in MCT cells was II and III, the strong expression of Akt was noticed in cytoplasm in majority of MCT cells. In this study, three immunolabelling locations of p-Akt were found including cytoplasmic only, diffuse in cytoplasm with loose distribution in nucleus, and diffuse in cytoplasm with dense distribution in nucleus. There was a significant difference between immunostaining patterns of KIT and immunolabelling locations of p-Akt (P = 0.005). When the immunostaining pattern of KIT was pattern I, the major immunolabelling locations of p-Akt was cytoplasm only (70.0%, 7/10). However, when the immunostaining pattern of KIT was pattern III, the major immunolabelling locations of p-Akt was diffuse in cytoplasm and nucleus (61.5%, 8/13). A significant difference was observed between immunolabelling locations of p-Akt and metastasis (P = 0.001). The majority of p-Akt immunolabelling locations without MCT metastasis was cytoplasmic only (51.7%, 15/27), while the majority of p-Akt immunolabelling locations with MCT metastasis was diffuse in cytoplasm with dense distribution in nucleus (57.1%, 12/21). The overexpression and increase of activity of mTOR were showed when activity of p-Akt enhanced. This study highlighted the importance of KIT/PI3K/Akt/mTOR signaling pathway in canine cutaneous MCTs and p-Akt plays an important role in metastasis of MCTs.
其他識別: U0005-2811201416190083
文章公開時間: 10000-01-01
Appears in Collections:獸醫學系所



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.